Literature DB >> 17297462

CDX2 promotes anchorage-independent growth by transcriptional repression of IGFBP-3.

S Y Chun1, F Chen, J G Washburn, J W MacDonald, K L Innes, R Zhao, M R Cruz-Correa, L H Dang, D T Dang.   

Abstract

CDX2 is a Drosophila caudal-related homeobox transcription factor that is important for the establishment and maintenance of intestinal epithelial cells. We have reported that CDX2 promotes tumorigenicity in a subset of human colorectal cancer cell lines. Here, we present evidence that CDX2 negatively regulates the well-documented growth inhibitor insulin-like growth factor binding protein-3 (IGFBP-3). Specifically, CDX2 binds to the IGFBP-3 gene promoter and can repress IGFBP-3 transcription, protein expression and secretion. Furthermore, inhibition of IGFBP-3 partially rescues the decreased anchorage-independent growth phenotype observed in CDX2 knockout cells. These data demonstrate for the first time that (1) CDX2 can function as a transcriptional repressor, and (2) one mechanism by which CDX2 promotes anchorage-independent growth is by transcriptional repression of IGFBP-3.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17297462     DOI: 10.1038/sj.onc.1210258

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

1.  Intestine-specific transcription factor Cdx2 induces E-cadherin function by enhancing the trafficking of E-cadherin to the cell membrane.

Authors:  Shinsuke Funakoshi; Jianping Kong; Mary Ann Crissey; Long Dang; Duyen Dang; John P Lynch
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-07-29       Impact factor: 4.052

Review 2.  Targeting insulin-like growth factor-I and insulin-like growth factor-binding protein-3 signaling pathways. A novel therapeutic approach for asthma.

Authors:  Hyun Lee; So Ri Kim; Youngman Oh; Seong Ho Cho; Robert P Schleimer; Yong Chul Lee
Journal:  Am J Respir Cell Mol Biol       Date:  2014-04       Impact factor: 6.914

3.  ATM gene mutations result in both recessive and dominant expression phenotypes of genes and microRNAs.

Authors:  Denis A Smirnov; Vivian G Cheung
Journal:  Am J Hum Genet       Date:  2008-08       Impact factor: 11.025

4.  BP1 Homeoprotein Enhances Metastatic Potential in ER-negative Breast Cancer.

Authors:  Yebo Fu; Yi Lian; Kyung Soon Kim; Lei Zhang; A Katharine Hindle; Fred Brody; Robert S Siegel; Timothy A McCaffrey; Sidney W Fu
Journal:  J Cancer       Date:  2010-06-24       Impact factor: 4.207

5.  Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1α and HIF-2α target genes.

Authors:  Sang Y Chun; Craig Johnson; Joseph G Washburn; Marcia R Cruz-Correa; Duyen T Dang; Long H Dang
Journal:  Mol Cancer       Date:  2010-11-13       Impact factor: 27.401

Review 6.  Unraveling insulin-like growth factor binding protein-3 actions in human disease.

Authors:  Sherryline Jogie-Brahim; David Feldman; Youngman Oh
Journal:  Endocr Rev       Date:  2009-05-28       Impact factor: 19.871

7.  ERK phosphorylation is predictive of resistance to IGF-1R inhibition in small cell lung cancer.

Authors:  Rebekah L Zinn; Eric E Gardner; Luigi Marchionni; Sara C Murphy; Irina Dobromilskaya; Christine L Hann; Charles M Rudin
Journal:  Mol Cancer Ther       Date:  2013-03-20       Impact factor: 6.261

8.  Caudal homeobox protein Cdx-2 cooperates with Wnt pathway to regulate claudin-1 expression in colon cancer cells.

Authors:  Ajaz A Bhat; Ashok Sharma; Jillian Pope; Moorthy Krishnan; Mary K Washington; Amar B Singh; Punita Dhawan
Journal:  PLoS One       Date:  2012-06-15       Impact factor: 3.240

9.  Local IGFBP-3 mRNA expression, apoptosis and risk of colorectal adenomas.

Authors:  Temitope O Keku; Robert S Sandler; James G Simmons; Joseph Galanko; John T Woosley; Michelle Proffitt; Oluwaseun Omofoye; Maya McDoom; Pauline K Lund
Journal:  BMC Cancer       Date:  2008-05-22       Impact factor: 4.430

10.  A novel CDX2 isoform regulates alternative splicing.

Authors:  Matthew E Witek; Adam E Snook; Jieru E Lin; Erik S Blomain; Bo Xiang; Michael S Magee; Michael Magee; Scott A Waldman
Journal:  PLoS One       Date:  2014-08-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.